Literature DB >> 21418690

Leprosy.

W Cairns S Smith1, Paul Saunderson.   

Abstract

INTRODUCTION: The World Health Organization field leprosy classification is based on the number of skin lesions: paucibacillary leprosy (1-5 skin lesions), and multibacillary leprosy (more than 5 skin lesions). Worldwide, about 250,000 new cases of leprosy are reported each year, and about 2 million people have leprosy-related disabilities. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent leprosy? What are the effects of treatments for leprosy? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 20 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: chemoprophylaxis with single-dose rifampicin, Bacillus Calmette-Guerin (BCG) plus killed Mycobacterium leprae vaccine, BCG vaccine, ICRC vaccine, multidrug treatment, multiple-dose treatment, Mycobacterium w vaccine, and single-dose treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21418690      PMCID: PMC3217821     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  40 in total

1.  Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group.

Authors: 
Journal:  Lancet       Date:  1996-07-06       Impact factor: 79.321

2.  Risk of relapse in leprosy after fixed-duration multidrug therapy.

Authors:  H Y Li; L F Hu; W B Huang; G C Liu; L C Yuan; Z Jin; X Li; J L Li; Z M Yang
Journal:  Int J Lepr Other Mycobact Dis       Date:  1997-06

3.  Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi.

Authors:  G Boerrigter; J M Pönnighaus; P E Fine; R J Wilson
Journal:  Int J Lepr Other Mycobact Dis       Date:  1991-06

4.  A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996.

Authors:  K Dasananjali; P A Schreuder; C Pirayavaraporn
Journal:  Int J Lepr Other Mycobact Dis       Date:  1997-03

5.  Effect of HIV infection on leprosy: a three-year survey in Bamako, Mali.

Authors:  C Lienhardt; B Kamate; P Jamet; A Tounkara; O C Faye; S O Sow; P Bobin
Journal:  Int J Lepr Other Mycobact Dis       Date:  1996-12

Review 6.  The management of erythema nodosum leprosum: current and future options.

Authors:  D N Lockwood
Journal:  Lepr Rev       Date:  1996-12       Impact factor: 0.537

7.  BCG vaccination of children against leprosy: fourteen-year findings of the trial in Burma.

Authors:  K Lwin; T Sundaresan; M M Gyi; L M Bechelli; C Tamondong; P G Garbajosa; H Sansarricq; S K Noordeen
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

Review 8.  Chemotherapy of leprosy. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1994

9.  A clinicopathological study of multidrug therapy in borderline tuberculoid leprosy.

Authors:  P K Kar; P N Arora; C V Ramasastry; R S Dhaka
Journal:  J Indian Med Assoc       Date:  1994-10

10.  Extended studies on the viability of Mycobacterium leprae outside the human body.

Authors:  K V Desikan
Journal:  Lepr Rev       Date:  1995-12       Impact factor: 0.537

View more
  1 in total

1.  A comprehensive research agenda for zero leprosy.

Authors:  Peter Steinmann; Courtenay Dusenbury; David Addiss; Fareed Mirza; W Cairns S Smith
Journal:  Infect Dis Poverty       Date:  2020-11-12       Impact factor: 4.520

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.